Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Claritas Pharmaceuticals Inc V.CLAS.H

Alternate Symbol(s):  CLAZF

Healthcare
Claritas Pharmaceuticals, Inc., formerly Kalytera Therapeutics Inc, is a biotechnology company that is focused on developing R-107 for the treatment of vaccine-resistant coronavirus disease (COVID) strains. The Company’s products in development include R-107 for coronavirus disease and Viral Infections, R-107 and Vaccines, and CLA-1816 for treatment of pain. R-107 is designed to defeat COVID viruses on contact. R-107 targets the Achilles heel of COVID, the spike protein on the surface of the virus. R-107 releases nitric oxide, which attaches to a specific amino acid on the spike protein, thereby disabling the spike protein. The CLA-1816 provides effective pain reduction, without the risks of addiction or respiratory suppression that exist with opioid analgesics. CLA-1816 strongly binds with and activates the alpha3 glycine pain receptor in the spine. The Company has leased a laboratory, office, and archival space in Beverly, Massachusetts.


TSXV:CLAS.H - Post by User

Claritas Pharmaceuticals Inc
Bullboard Posts
User Avatar Image
(3)
•••
Comment by alejo.g3ologiston Jun 05, 2019 10:52am
73 Views
Post# 29799859

RE:RE:RE:RE:RE:RE:RE:Kly now 0.05 , chart says going over 0.10

RE:RE:RE:RE:RE:RE:RE:Kly now 0.05 , chart says going over 0.10
TheGoy wrote: I have found TA to be absolutely essential in making all of my investment decisions... even when investing in penny stocks. TA applies to all aspects of market activity and in all areas of trade. Just like any other data bank, TA has a variety of interpretive techniques for developing insight into any given angle that you choose to view the market/stock from... you just have to know which technique to use (and how to interpret it) in a given situation. The personality of a recently listed penny stock in an explosive new industry can have extreme variations in character from that of a $50.00 blue chip that has established it's foot hold over the decades but the movements (historical trades and subsequent probabilities) of each are explained by the same fundamental and technical analysis tools. One simply needs to know how to filter the information these investigative methods provide us with. Obviosuly...  those who don't understand how to use the tools correctly will not find them very useful. Just saying....


ok, enlighten us with the TA applied un Kly...what can be interpreted the TA on kly?

Bullboard Posts
Dealroom for high-potential pre-IPO opportunities